Screener
Acadia Pharmaceuticals ACAD Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net income | $35,137 | $45,653 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Stock-based compensation | 31,638 | 25,720 |
| Amortization of premiums and accretion of discounts on investment securities | (503) | (3,652) |
| Amortization of intangible assets | 5,445 | 5,444 |
| Depreciation | 705 | 442 |
| Deferred Income Taxes | 9,679 | — |
| Changes in operating assets and liabilities: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Acadia Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
- Acadia Pharmaceuticals (ACAD) reported accretion (amortization) of discounts and premiums, investments of $50K in Q2 2026.
- How has Acadia Pharmaceuticals's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Acadia Pharmaceuticals's accretion (amortization) of discounts and premiums, investments decreased by 96.7% year-over-year, from $1.54M to $50K.
- What is the long-term trend for Acadia Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
- Over 4 years (2021 to 2025), Acadia Pharmaceuticals's accretion (amortization) of discounts and premiums, investments has grown at a 22.6% compound annual growth rate (CAGR), from -$2.4M to $5.42M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to net income for the amortization of premiums or the accretion of discounts on debt securities held as investments. It reflects the gradual adjustment of the carrying value of investment securities toward their face value over time. Investors use this to reconcile reported net income with actual cash flows generated from investment portfolios.
Ask your AI about Acadia Pharmaceuticals's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude